Cidara Therapeutics Statistics
Total Valuation
CDTX has a market cap or net worth of $227.39 million. The enterprise value is $40.32 million.
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025, after market close.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CDTX has 10.95 million shares outstanding. The number of shares has increased by 45.26% in one year.
| Current Share Class | 10.95M |
| Shares Outstanding | 10.95M |
| Shares Change (YoY) | +45.26% |
| Shares Change (QoQ) | +48.97% |
| Owned by Insiders (%) | 1.01% |
| Owned by Institutions (%) | 14.18% |
| Float | 3.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 103.01 |
| Forward PS | n/a |
| PB Ratio | 1.39 |
| P/TBV Ratio | 1.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 31.63 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.25, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.25 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -219.59% and return on invested capital (ROIC) is -69.72%.
| Return on Equity (ROE) | -219.59% |
| Return on Assets (ROA) | -40.46% |
| Return on Invested Capital (ROIC) | -69.72% |
| Return on Capital Employed (ROCE) | -55.20% |
| Revenue Per Employee | $33,553 |
| Profits Per Employee | -$4.47M |
| Employee Count | 38 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +52.42% in the last 52 weeks. The beta is 0.89, so CDTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +52.42% |
| 50-Day Moving Average | 21.40 |
| 200-Day Moving Average | 16.87 |
| Relative Strength Index (RSI) | 53.88 |
| Average Volume (20 Days) | 174,694 |
Short Selling Information
The latest short interest is 470,336, so 4.29% of the outstanding shares have been sold short.
| Short Interest | 470,336 |
| Short Previous Month | 289,926 |
| Short % of Shares Out | 4.29% |
| Short % of Float | 13.18% |
| Short Ratio (days to cover) | 3.12 |
Income Statement
In the last 12 months, CDTX had revenue of $1.28 million and -$169.83 million in losses. Loss per share was -$26.75.
| Revenue | 1.28M |
| Gross Profit | -70.60M |
| Operating Income | -91.22M |
| Pretax Income | -36.02M |
| Net Income | -169.83M |
| EBITDA | -91.07M |
| EBIT | -91.22M |
| Loss Per Share | -$26.75 |
Full Income StatementBalance Sheet
The company has $189.83 million in cash and $3.58 million in debt, giving a net cash position of $186.25 million or $17.00 per share.
| Cash & Cash Equivalents | 189.83M |
| Total Debt | 3.58M |
| Net Cash | 186.25M |
| Net Cash Per Share | $17.00 |
| Equity (Book Value) | 163.31M |
| Book Value Per Share | 14.92 |
| Working Capital | 161.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$176.53 million and capital expenditures -$129,000, giving a free cash flow of -$176.66 million.
| Operating Cash Flow | -176.53M |
| Capital Expenditures | -129,000 |
| Free Cash Flow | -176.66M |
| FCF Per Share | -$16.13 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -7,154.43% |
| Pretax Margin | -13,356.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CDTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -45.26% |
| Shareholder Yield | -45.26% |
| Earnings Yield | -74.95% |
| FCF Yield | -77.97% |
Analyst Forecast
The average price target for CDTX is $38.00, which is 83.04% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.00 |
| Price Target Difference | 83.04% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 150.22% |
| EPS Growth Forecast (5Y) | -50.02% |
Stock ForecastsStock Splits
The last stock split was on April 24, 2024. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Apr 24, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
CDTX has an Altman Z-Score of -3.45 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.45 |
| Piotroski F-Score | 1 |